Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q2 2015 Earnings Presentation
18 slides from Bactiguard Holding Ab's earnings presentation, Aug 13, 2015
Slide 1: Innovating for the healthcare needs of today and tomorrow
Innovating for the healthcare needs of today and tomorrow Q2 presentation 13 August 2015
Slide 2: Our Mission
Our Mission To prevent device related healthcare associated infections Reduce healthcare cost Reduce the use of antibiotics Prevent spread of multi-resistant bacteria Save lives 2
Slide 3: Healthcare associated infections – the most frequent adverse event in health care
Healthcare associated infections – the most frequent adverse event in health care *Sweden 9% Canada 11.6% EU average ~7% USA 4.5% Turkey 12.5% Iraq ~20% Tanzania 15% Brazil 14% New Zeeland 12% Prevalence of healthcare associated infections Source: WHO/Patient Safety/Report on the Burden of Endemic H
Slide 4: Healthcare associated infections is increasing
Healthcare associated infections is increasing Patients with healthcare associated infections in Sweden 12% 10% 8% 6% 4% 2% 0% VT 08 HT 08 VT 09 HT 09 VT 10 HT 10 VT 11 HT 11 VT 12 HT 12 VT 13 HT 13 VT 14 VT 15 Andel patienter med VRI Source: Sveriges Kommuner och Landsting (SKL), May 2015 4
Slide 5: Travel increases risk of multiresistant bacteria
Antimicrobial resistance Travel increases risk of multiresistant bacteria More people travel than ever before Travelers are exposed to increased infection risk 50 percent of travelers returning from South Asia, carry multi resistant bacteria* Seeking medical care in a country with a high lev
Slide 6: Bactiguard Infection Protection
Targets the most common HAIs Bactiguard Infection Protection ...explaining the rationale behind the products in Occurrence of HAI US (all hospital types) the Bactiguard portfolio Other Urinary tract BIP Foley 17% 32% Surgical site 22% 14% 15% Blood stream BIP ETT Respiratory tract Medical devices, f
Slide 7: Second quarter performance
Second quarter performance • Positive volume development in our BIP portfolio • Highest deliveries since Q4 2013 • Repeat orders from Saudi Arabia, market contribution consumed • Initial deliveries to Angola and Switzerland • Revenues and earnings weaker than in 2014 • Stable underlying license busi
Slide 8: Revenue streams
Financial overview Revenue streams Three revenue streams in the income statement License BIP portfolio Bard license deal BIP Foley BIP ETT BIP CVC (sales since 1995) 1 2 3 License Territorial fee BIP revenue From a product perspective Bactiguard has two lines of business; Licenses and the BIP portfo
Slide 9: Highlights
Financial overview Highlights Second quarter (April-June 2015) • Revenues of MSEK 27.7 (31.2), minus 11% compared to 2014 (no Territorial fees in Q2 2015, compared to 4.8 MSEK in Q2 2014) • EBITDA of MSEK -10 (2.2). Excluding provision for doubtful accounts receivable and severance pay, EBITDA adjus
Slide 10: Supplied products
Financial overview Supplied products • 58 000 BIP products supplied in Q2 2015 compared to approximately 44 000 during Q2 2014, an increase by 32%. • For the first half year 2015, 63 000 BIP products were supplied compared to 60 000 for the corresponding period in 2014. • For the full year 2014, 79
Slide 11: Income distribution
Financial overview Income distribution Apr-Jun Apr-Jun Jan-Jun MSEK 2015 2014 2015 License revenues 25,8 22,8 52,6 Territorial fees - 4,8 - Sales of BIP products 1,0 1,5 1,1 Other revenue 0,9 2,1 2,8 Total Revenues 27,7 31,2 56,6 11
Slide 12: License revenues
Financial overview License revenues License revenues (SEKm) Q1 Q2 H1 Q3 Q4 Full year Of which 2013 21,6 19,3 40,9 21,3 20,5 82,7 currency effect 2014 22,5 22,8 45,3 24,3 20,2 89,8 MSEK 4 m 2015 26,8 25,8 52,6 Of which currency effect MSEK 11 m USD/SEK 2013 2014 H1 2014 H1 2015 Average 6,51 6,86 6,53
Slide 13: Key figures
Financial overview Key figures Apr-Jun Apr-Jun Jan-Jun Key figures • EBITDA (Q2) MSEK -10.0, 2015 2014 2015 adjusted EBITDA MSEK -3.4 Revenues, SEKm 27,7 31,2 56,6 EBITDA, SEKm -10,0 2,2 -36,8 EBITDA margin, % -36% 7% -65% • EBITDA (First half) MSEK EBITDA*, SEKm -10,0 5,2 -36,8 -36.8, adjusted EBIT
Slide 14: Financial flexibility and strength
Financial overview Financial flexibility and strength Q2 -14 Share issue of MSEK 20 in April Set off issue of MSEK 222.5 in June Share issue of MSEK 240 in connection with IPO • Repurchase of bonds, nominal value MSEK 44 • Equity ratio of 64 % • Net debt of MSEK 88.5 • Cash position of MSEK 84
Slide 15: Focus on high potential markets and regions
Focus on high potential markets and regions 15
Slide 16: Transfer of production
Transfer of production Production HQ transfer CE audit start December 2014 May 2015 June July August September BIP CVC BIP ETT validation validation, inventory transfer
Slide 17: Investing in Bactiguard is investing in the future
Investing in Bactiguard is investing in the future • Healthcare associated infections and antibiotic resistance - two of the greatest challenges of our time • Prevention is key - Bactiguard has efficient, safe and well proven solutions • Secure stability and continuity • Expand business, both intern
Slide 18: For more information
For more information Please visit our website: www.bactiguard.com For questions and additional information, please contact: Christian Kinch, CEO: +46 8 440 58 80 christian.kinch@bactiguard.se Fredrik Järrsten, CFO: +46 725 500 089 fredrik.jarrsten@bactiguard.se Cecilia Edström, Director of Sales, Ma